CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) VP David Foehr sold 859 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $23.95, for a total transaction of $20,573.05. Following the sale, the vice president owned 35,899 shares of the company’s stock, valued at approximately $859,781.05. This represents a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
David Foehr also recently made the following trade(s):
- On Friday, August 21st, David Foehr sold 993 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total transaction of $23,851.86.
CeriBell Stock Down 0.3%
CBLL opened at $23.37 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The company has a market capitalization of $896.94 million, a PE ratio of -13.28 and a beta of 0.81. CeriBell, Inc. has a fifty-two week low of $10.85 and a fifty-two week high of $25.33. The business has a 50-day moving average of $20.00 and a 200-day moving average of $19.32.
Wall Street Analyst Weigh In
CBLL has been the topic of several recent analyst reports. Canaccord Genuity Group lifted their price target on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Barclays upgraded shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. Finally, BTIG Research lifted their price objective on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, CeriBell currently has a consensus rating of “Moderate Buy” and an average price target of $22.40.
View Our Latest Research Report on CeriBell
Hedge Funds Weigh In On CeriBell
Hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. increased its stake in shares of CeriBell by 6,424.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock worth $7,117,000 after purchasing an additional 374,179 shares during the last quarter. Rhumbline Advisers boosted its position in shares of CeriBell by 109.9% in the second quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock valued at $614,000 after acquiring an additional 17,177 shares during the period. New York State Common Retirement Fund increased its holdings in shares of CeriBell by 148.6% during the second quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock worth $163,000 after purchasing an additional 5,200 shares during the period. Quantbot Technologies LP lifted its position in shares of CeriBell by 70.3% during the 2nd quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock valued at $290,000 after acquiring an additional 6,401 shares during the period. Finally, Invesco Ltd. bought a new position in CeriBell in the 2nd quarter valued at about $197,000.
About CeriBell
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
See Also
- Five stocks we like better than CeriBell
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
